Last reviewed · How we verify
Fluarix-AS50
At a glance
| Generic name | Fluarix-AS50 |
|---|---|
| Also known as | Fluarix vaccine adjuvanted with AS25 |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population (PHASE2)
- Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluarix-AS50 CI brief — competitive landscape report
- Fluarix-AS50 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI